181 related articles for article (PubMed ID: 9075767)
1. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.
Kawakami Y; Battles JK; Kobayashi T; Ennis W; Wang X; Tupesis JP; Marincola FM; Robbins PF; Hearing VJ; Gonda MA; Rosenberg SA
J Immunol Methods; 1997 Mar; 202(1):13-25. PubMed ID: 9075767
[TBL] [Abstract][Full Text] [Related]
2. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
Lee SW; Li H; Strong TV; Moore SE; Conry RM
J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.
Fetsch PA; Marincola FM; Filie A; Hijazi YM; Kleiner DE; Abati A
Cancer; 1999 Feb; 87(1):37-42. PubMed ID: 10096358
[TBL] [Abstract][Full Text] [Related]
4. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
Surman DR; Irvine KR; Shulman EP; Allweis TM; Rosenberg SA; Restifo NP
J Immunol Methods; 1998 May; 214(1-2):51-62. PubMed ID: 9692858
[TBL] [Abstract][Full Text] [Related]
5. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
[TBL] [Abstract][Full Text] [Related]
6. Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies.
Bystryn JC; Jacobsen JS; Liu P; Heaney-Kieras J
Hybridoma; 1982; 1(4):465-72. PubMed ID: 6208141
[TBL] [Abstract][Full Text] [Related]
7. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.
Marincola FM; Hijazi YM; Fetsch P; Salgaller ML; Rivoltini L; Cormier J; Simonis TB; Duray PH; Herlyn M; Kawakami Y; Rosenberg SA
J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):192-205. PubMed ID: 8811494
[TBL] [Abstract][Full Text] [Related]
8. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
[TBL] [Abstract][Full Text] [Related]
9. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.
Nicotra MR; Nisticò P; Mangoni A; Di Filippo F; Marincola FM; Natali PG
J Immunother; 1997 Nov; 20(6):466-9. PubMed ID: 9409452
[TBL] [Abstract][Full Text] [Related]
10. Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas.
Fetsch PA; Cormier J; Hijazi YM
J Immunother; 1997 Jan; 20(1):60-4. PubMed ID: 9101414
[TBL] [Abstract][Full Text] [Related]
11. Unique proteins defined by monoclonal antibodies specific for human melanoma. Some potential clinical applications.
Esclamado RM; Gown AM; Vogel AM
Am J Surg; 1986 Oct; 152(4):376-85. PubMed ID: 3766867
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution of a melanoma-associated antigen immunogenic in patients with melanoma as analyzed by polyclonal antibodies to recombinant peptide antigen.
Kako S; Hayashibe K; Ichihashi M
J Dermatol; 1996 Apr; 23(4):230-7. PubMed ID: 8935336
[TBL] [Abstract][Full Text] [Related]
13. Analysis of hybridoma-exchange antibodies.
Lloyd KO; Albino A; Houghton A
Hybridoma; 1982; 1(4):461-3. PubMed ID: 6208140
[No Abstract] [Full Text] [Related]
14. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
15. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.
Chen YT; Stockert E; Jungbluth A; Tsang S; Coplan KA; Scanlan MJ; Old LJ
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5915-9. PubMed ID: 8650193
[TBL] [Abstract][Full Text] [Related]
16. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.
Wang X; Campoli M; Cho HS; Ogino T; Bandoh N; Shen J; Hur SY; Kageshita T; Ferrone S
J Immunol Methods; 2005 Apr; 299(1-2):139-51. PubMed ID: 15896802
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.
Reinke S; Königer P; Herberth G; Audring H; Wang H; Ma J; Guo Y; Sterry W; Trefzer U
Am J Dermatopathol; 2005 Oct; 27(5):401-6. PubMed ID: 16148409
[TBL] [Abstract][Full Text] [Related]
18. Development of MoAb HMSA-3 and HMSA-4 against human melanoma melanosomes and their reactivities on formalin-fixed melanoma tissues.
Maeda K; Yamana K; Jimbow K
J Invest Dermatol; 1987 Dec; 89(6):588-93. PubMed ID: 3680982
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of MART-1 in primary and metastatic melanoma lesions.
Kageshita T; Kawakami Y; Hirai S; Ono T
J Immunother; 1997 Nov; 20(6):460-5. PubMed ID: 9409451
[TBL] [Abstract][Full Text] [Related]
20. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
